Visiongain Publishes Cardiovascular Repair and Reconstruction Devices Market Report 2020-2030

02 August 2020
Pharma

Visiongain has launched a new pharma report Cardiovascular Repair and Reconstruction Devices Market Report 2020-2030: Prospects by Product (Heart Valve Repair, Cardiovascular Graft (Endovascular Stent Graft, Hemodialysis Access Graft, Peripheral Vascular Graft), Cardiovascular Patches (Cardiac repair patches, Vascular Repair Patches)), Raw Material (Synthetic Patches, Biological Patches), Applications (Knee Injuries, Shoulder Injuries, Foot & Ankle Injuries, Hip & Groin Injuries, Elbow & Wrist Injuries, Back & Spine Injuries, Other Injuries), and Geography.

The global Cardiovascular Repair and Reconstruction Devices market is projected to grow at a lucrative CAGR of ~xx% and anticipated to surpass USD xx billion by 2030.

The presence of technologically enhanced cryopreservation techniques, changing lifestyles, and growing chronic diseases are documented as major factors in the industry of cardiovascular repair and reconstruction devices that are estimated to boost growth in the years to come. Cost-related issues, however, can restrict the overall market growth in the years to come.

Transcatheter valve introduction has increased the demand for tissue valves. Transcatheter Aortic Valve Implantation (TAVI) or Transcatheter Aortic Valve Replacement (TAVR) is an FDA-approved technique for the treatment of symptomatic aortic stenosis in heart valve replacement. Some of the established players in the TAVR market are Edwards Lifesciences, Medtronic, Meril Life Sciences Pvt. Ltd., and St. Jude Medical, Inc. among other prominent players.

Also, JenaValve, a Germany-based company, has successfully enrolled in the CE mark study for the next JenaValve Pericardial TAVR gene in April 2018. It is expected that the entry of new players with advanced technology will boost market growth significantly over the forecast period.

Furthermore, the growth of the market for cardiovascular repair & reconstruction devices is dependent upon advancement in technology such as advanced cryopreservation techniques. They help preserve raw materials extracted from animal tissues for a long time, and this plays a crucial role in increasing their life cycle. These technological developments have a positive impact on the growth of the industry by increasing demand for cardiovascular grafts or patches.

The global cardiovascular repair and reconstruction market is dominated by the North American region and similar dominance is anticipated over the forecast period. The reason behind overall market growth is attributed to an unhealthy lifestyle and growing geriatric population, high adoption rate of advance technology, development of research centers with state-of-the-art technology, and growth in healthcare facilities across the region. The United States is a major consumer in the field for cardiac repair and replacement products owing to rising chronic diseases such as cardiovascular disease, cancer, arthritis, and diabetes, as well as the presence of technologically advanced products in the region.

It is anticipated that the Asia Pacific will experience the fastest growth over the forecast period. The growth is attributed to its growing patient pool, rising aging population, high unmet healthcare needs and changing lifestyles. Japan, China, & India are the emerging economies across the Asia Pacific region which are offering lucrative opportunities for revenue generation across the Asia Pacific region. Furthermore, improvements in the region's healthcare system and the presence of global major players are also anticipated to fuel cardiovascular repair and reconstruction market growth over the forecast period.

Some of the major players operating in this industry are Arthrex, Inc., Admedus Ltd, Bard Peripheral Vascular, Bauerfeind AG, Breg, Inc., Conmed Corporation, CorMatrix, Cryolife, Depuy Synthes Companies, DJO Global, Inc., Edwards Lifesciences Corporation, KARL STORZ GmbH & Co.Kg, LeMaitre Vascular, Inc., MAQUET Cardiovascular, LLC, Medtronic PLC, Mueller Sports Medicine, Inc., Performance Health International Limited, Reverse Medical Corporation, RTI Surgical Holdings, Inc., Smith & Nephew PLC among other prominent players.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes RNA Analysis/Transcriptomics Market Report 2020-2030

Rising preference for personalised medicine in developed as well developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase RNA analysis/transcriptomics market concentration over the forecast period. In order to increase the reliability and success rate of the drug production process.

30 November 2020

Read

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

Read

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

Read

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever